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Background
In this paper we describe how we sought approval and
are implementing a diagnostic service for malignant
hyperthermia (MH) using clonal targeted next genera-
tion sequencing.
Approval required submission of a gene dossier to the
UK Genetic Testing Network. This document included:
1. An overview of MH and the evidence for involve-
ment of RYR1 and CACNA1S;
2. Details of the genes
3. Current diagnostic approaches
4. Proposed sequencing strategy
5. Gene coverage with proposed strategy
6. Validation strategy
7. Genetic epidemiology of MH
8. Test characteristics (sensitivity, specificity, PPV,
NPV)
9. Cost benefit of new test
10. Referral criteria
Following adoption of the dossier by the UGTN and
validation of the sequencing strategy in a diagnostic
facility, we are now in a position to offer testing. Testing
will be offered to families where MH has been con-
firmed by IVCT and to new index cases. The cost of the
sequencing is £530, compared to £3,500 for the IVCT.
For index cases, the referring physician will be advised
of the pre-test probability for their patient having MH
as they may consider IVCT to be more cost-effective
when the pre-test probability is low.
Diagnostic reports will be issued in accordance with
the joint guideline of the UK Association of Clinical
Genetic Science (ACGS) and the Dutch Society of Clini-
cal Genetic Laboratory Specialists (VKGL). Variants will
be classified using a 5 class system:
Reports for classes 1 – 3 will advise IVCT.
Variants will be assigned to a class depending on their
reported frequency in databases (dbSNP, 1000 Genomes,
EVS), segregation analysis and functional analysis.
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Table 1 5 Class System
Class Description Interpretation
1 Clearly not pathogenic MH not confirmed or
excluded
2 Unlikely to be pathogenic MH not confirmed or
excluded
3 Variant of unknown significance
(VUS)
MH not confirmed or
excluded
4 Likely to be pathogenic Consistent with diagnosis
5 Clearly pathogenic Confirms diagnosis
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